Mar 28, 2023 | Case studies

Cost-effective drug safety systems and solutions

A small pharma client with limited budget had several clinical compounds in Phase I and II, and one globally approved commercial product. They required robust processes for the evaluation of single and aggregate data to strengthen stakeholder review and documentation management associated with serious adverse events (SAEs).

Qinecsa-CaseStudy-CosteffectiveDrugSafetySolutions_Mar23

Download pdf

Resources

Find out more

Join Qinecsa at 32nd Pharmacovigilance 2023, 26-27 April, Boston

19.04.2023 | News

Join Qinecsa at 32nd Pharmacovigilance 2023 to discuss the latest developments in pharmacovigilance, drug safety & risk management.Our President, Humaira Qureshi, will present ‘Fit for future sourcing for pharmacovigilance’ where she will discuss the drivers for...

Signal & risk management

31.03.2023 | Fact sheets

Qinecsa provides tailored signal detection and risk management services for clinical and commercial products, including associated benefit-risk management activities. With diverse therapeutic expertise and industry-leading technology, our team support the breadth and...

CVW platform

31.03.2023 | Fact sheets

The Commonwealth Vigilance Workbench (CVW) signal detection platform spans the full spectrum of the signal management process to ensure all potential signals are tracked with clear prioritization. Robust data integration and functionality enables analysis of aggregate...